Skip to main content
Log in

Nitroglycerin for ergotism. Experimental studies in vitro and in migraine patients and treatment of an overt case

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Ergotamine was used to induce arterial contraction in vitro (measurement of isometric tension in segments from 3 human temporal arteries) and in vivo (peripheral systolic blood pressure measured by strain gauge plethysmography in 5 migrainous patients). In both these models of ergotism, the directly acting vasodilator nitroglycerine (NTG) effectively relieved the ergotamine-induced arterial contractions. A case of ergotism treated succesfully with NTG infusion is reported. The diagnosis was based on history and measurement of peripheral systolic blood pressure by strain gauge plethysmography. The latter technique was also used to monitor the response to treatment for 20 h. Blood levels of ergotamine during ergotism were in the therapeutic range. Possible explanations for this finding are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Krupp P, Haas G (1979) Effets indesirables et interactions medicamenteuses des alcaloides de l'ergot de seigle. J Pharmacol (Paris) 10: 401–12

    Google Scholar 

  2. Hessov I, Kromann-Andersen C, Madsen B (1972) Peripheral arterial insufficiency during ergotamine treatment. Course of disease, angiographic findings and treatment by phenoxybenzamine. Dan Med Bull 19: 236–44

    Google Scholar 

  3. Carliner NH, Denune DP, Finch Jr CS, Goldberg LI (1974) Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia. J Am Med Assoc 227: 308–9

    Google Scholar 

  4. Husum B, Metz P, Rasmussen JP (1979) Nitroglycerin infusion for ergotism. Lancet II: 794–95

    Google Scholar 

  5. Müller-Schweinitzer E (1976) Evidence for stimulation of 5-HT receptors in canine saphenous arteries by ergotamine. Naunyn-Schmiedberg's Arch Pharmacol 295: 41–44

    Google Scholar 

  6. Tfelt-Hansen P, Eickhoff JH, Olesen J (1980) The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients. Methodological aspects and time effect curve. Acta Pharmacol Toxicol 47: 151–56

    Google Scholar 

  7. Østergaard JR, Voldby B (1981) Altered extracranial reactivity in patients with cerebral arterial aneurysm: An in vitro study. Surg Neurol 15: 47–50

    Google Scholar 

  8. Edlund P-O (1981) Determination of ergot alkaloids in plasma by high performance liquid chromatography and fluorescence detection. J Chromatogr 226: 107–15

    Google Scholar 

  9. Chu SY, Oliveras L, Deysai S (1980) Extraction procedure for measuring anticonvulsant drugs by liquid chromatography. Clin Chem 26: 521–22

    Google Scholar 

  10. Rothlin E, Cerletti A (1949) Untersuchungen über die Kreislaufswirkung des Ergotamins. Helv Physiol Acta 7: 333–70

    Google Scholar 

  11. Müller-Schweinitzer E, Weidman H (1977) Regional differences in the responsiveness of isolated arteries from cattle, dog and man. Agents Actions 7: 383–89

    Google Scholar 

  12. Ala-Hurula V, Myllylä VV, Arvela P, Heikkilä J, Kärki N, Hokkanen E (1979) Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. Eur J Clin Pharmacol 15: 51–55

    Google Scholar 

  13. Wolff HG (1962) Headache and other head pain. 2nd ed. Oxford University Press, Oxford

    Google Scholar 

  14. Krabbe AAe, Olesen J (1980) Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanism. Pain 8: 253–59

    Google Scholar 

  15. Merhoff GC, Porter JM (1974) Ergot intoxication: Historical review and description of unusual clinical manifestations. Ann Surg 180: 773–79

    Google Scholar 

  16. Dige-Petersen H, Lassen NA, Noer I, Tønnesen KH, Olesen J (1977) Subclinical ergotism. Lancet II: 65–66

    Google Scholar 

  17. Tfelt-Hansen P, Krabbe AÆ (1981) Ergotamine abuse. Do patients benefit from withdrawal? Cephalalgia 1: 29–32

    Google Scholar 

  18. Lavene D, Longchampt J, Guillaume MF, Kiger JL (1976) Drug interactions of the components of Optalidon after oral administration. Int J Clin Pharmacol 13: 235–45

    Google Scholar 

  19. Mayer SE, Melmore KL, Gilman AG (1980) In: Goodman LS, Gilman A (Eds) The pharmacological basis of therapeutics, 6th ed. Macmillan, New York, pp 23–24

    Google Scholar 

  20. Baumrucker JF (1973) Drug interaction-propranolol and cafergot. N Engl J Med 288: 916–17

    Google Scholar 

  21. Harrison TE (1978) Ergotaminism. J Am Coll Emergency Physicians 7: 162–69

    Google Scholar 

  22. Robinson BF, Dobbs RJ, Kelsey CR, Saverymuttu S (1981) A method for assesing responses of small arteries in man: effect of physiological and pharmacological stimuli. Clin Sci 60: 659–66

    Google Scholar 

  23. Kaplan JA, Finlayson DC, Woodwaed S (1980) Vasodilator therapy after cardiac surgery: A review of the efficacy and toxicity of nitroglycerin and nitroprusside. Can Anaesth Soc J 27: 254–59

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tfelt-Hansen, P., Østergaard, J.R., Gøthgen, I. et al. Nitroglycerin for ergotism. Experimental studies in vitro and in migraine patients and treatment of an overt case. Eur J Clin Pharmacol 22, 105–109 (1982). https://doi.org/10.1007/BF00542453

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542453

Key words

Navigation